WGS · GeneDx Holdings Corp.
Market Cap
$2.49B
Shares
29.82M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$427.54M
+40%
FY2025
Net Income
-$21.02M
+59.8%
FY2025
Gross Margin
69.74%
+6.1pp
FY2025
Operating Margin
-3.06%
+4.5pp
FY2025
Diluted EPS
-$0.73
+62.4%
FY2025
Operating Cash Flow
$33.28M
+216.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $454.43M | $427.54M | $305.45M | $202.57M | $234.69MG | $212.2M | $179.32M | $196.17M | |
| — | — | — | $1.11M | -$666K | — | — | — | |
| $139.18M | $129.37M | $111.05M | $112.56M | $261.44M | $228.8M | $175.3M | $113.39M | |
| $315.24M | $298.17M | $194.4M | $90.01M | -$26.75M | -$16.6M | $4.03M | $82.79M | |
| — | 69.74% | 63.64% | 44.43% | -11.4% | -7.82% | 2.25% | 42.2% | |
| $83.83M | $72.03M | $45.72M | $58.27M | $86.2M | $105.16M | $72.7M | $34.91M | |
| — | $88.41M | $67.37M | $60.96M | $122.08M | $112.74M | $63.18M | $39.35M | |
| — | $150.82M | $104.52M | $139.02M | $216.17M | $205.99M | $100.74M | $29.48M | |
| $10.9M | $9.6M | $7.9M | $19.7M | $50M | $21.81M | $11.73M | $6.41M | |
| — | — | $1.75M | $6.53M | $25.81M | — | — | — | |
| -$92.41M | -$13.08M | -$23.21M | -$180.6M | -$667.65M | -$446.15M | -$241.99M | -$30.41M | |
| — | -3.06% | -7.6% | -89.15% | -284.48% | -210.25% | -134.95% | -15.5% | |
| -$81.51M | -$3.48M | -$15.31M | -$160.9M | -$617.65M | -$424.34M | -$230.26M | -$24.01M | |
| $3M | — | — | — | $3.21M | $2.84M | $2.47M | $783K | |
| $4.56M | — | — | — | $2.54M | $79K | $506K | $988K | |
| -$13.88M | -$8.06M | -$29.42M | $3.9M | $69.62M | $200.76M | $654K | $709K | |
| -$106.3M | -$21.14M | -$52.63M | -$176.69M | -$598.03M | -$245.39M | -$241.34M | -$29.7M | |
| $62K | -$116K | -$343K | -$926K | -$49.05M | $0 | $0 | $0 | |
| -$106.36M | -$21.02M | -$52.29M | -$175.77M | -$548.98M | -$245.39M | -$241.34M | -$29.7M | |
| — | -4.92% | -17.12% | -86.77% | -233.91% | -115.64% | -134.58% | -15.14% | |
| — | — | — | — | — | -$245.39M | -$241.34M | -$32.74M | |
| -$106.83M | -$20.92M | -$51.88M | -$175.34M | -$548.98M | -$245.39M | -$241.34M | -$29.7M | |
| USD/shares | -$3.64 | -$0.73 | -$1.94 | -$7.23 | -$53.63 | -$74.91 | -$1,552,188.00 | -$8,713,848.00 |
| USD/shares | -$3.62 | -$0.73 | -$1.94 | -$7.23 | -$53.63 | -$74.91 | -$1,552,188.00 | -$8,713,848.00 |
| shares | — | 28.64M | 26.89M | 24.31M | 10.24M | 3.28M | 155.4848 | 3.7576 |
| shares | — | 28.64M | 26.89M | 24.31M | 10.24M | 3.28M | 155.4848 | 3.7576 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
5.41×
Peer median 2.89×
EV/EBIT
—
P/E (TTM)
—
Peer median 34.53×
Peer medians compare against the 21 similar-size Diagnostics & Research companies (of 47 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| GeneDx | $423,088,000 | $302,293,000 | $194,376,000 | $122,234,000 |
| All Other Segments | $4,451,000 | $3,157,000 | $8,190,000 | — |
| Legacy Sema4 | — | — | $8,190,000 | $112,460,000 |
| Other | — | $3,157,000 | $8,190,000 | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diagnostic Test Third Party Insurance | $345,235,000 | $234,699,000 | $134,491,000 | $173,624,000 | $169,576,000 | $138,153,000 | — |
| Diagnostic Test Institutional Customers | $70,072,000 | $65,115,000 | $59,497,000 | $46,124,000 | $31,717,000 | $35,200,000 | — |
| Product And Service Other | $10,871,000 | $3,293,000 | $6,912,000 | $7,360,000 | $7,095,000 | $3,971,000 | $4,507,000 |
| Diagnostic Test Self Pay | $1,361,000 | $2,343,000 | $1,666,000 | $7,586,000 | $3,807,000 | $1,998,000 | — |
| Diagnostic Test Institutional Customers | — | — | — | — | $31,717,000 | $35,200,000 | $20,888,000 |
| Diagnostic Test Self Pay | — | — | — | — | $3,807,000 | $1,998,000 | $1,241,000 |
| Diagnostic Test Third Party Insurance | — | — | — | — | $169,576,000 | $138,153,000 | $169,538,000 |
Key facts
CIK
1818331
CUSIP
81663L200
13F (30d)
186 filings
184 filers
Visit website
Investor relations